Addiction Helpline America Logo
Get Free & Confidential Help Now Who Answers?

FDA Approves First Test to Identify People at High Risk of Opioid Use Disorder

Published January 08, 2024 By Addiction Helpline

Naloxone

The ongoing opioid crisis in the United States represents one of the most profound public health challenges of our time. Initially fueled by the over-prescription of pain-relieving drugs in the 1990s and early 2000s, the crisis has evolved into a complex epidemic involving not only prescription opioids but also illicit drugs like heroin and synthetic opioids such as fentanyl. According to the Centers for Disease Control and Prevention (CDC), nearly 500,000 people died from opioid overdoses between 1999 and 2019. These staggering numbers highlight the deep and devastating impact of opioid misuse on individuals, families, and communities across the nation.

The crisis has transcended socio-economic, racial, and geographic boundaries, sparing no demographic or community. The impact is not just seen in mortality rates but also in the ripple effects on public health, social services, and the economy. Opioid addiction, or Opioid Use Disorder (OUD), can lead to a myriad of other health issues, including an increased risk of infectious diseases, mental health disorders, and chronic unemployment. Furthermore, the economic burden of the opioid crisis is immense, with the Council of Economic Advisers estimating the cost to be over $500 billion annually, including healthcare, lost productivity, addiction treatment, and criminal justice involvement.

This dire situation underscores the urgent need for innovative solutions. Traditional methods of addressing substance misuse, such as incarceration and abstinence-only treatments, have proven insufficient and, at times, counterproductive. There is a growing consensus among experts that a multifaceted approach is required, one that combines medical, psychological, and social strategies. Innovations are needed not only in the field of medicine, such as the development of new pharmacological treatments for addiction and pain management, but also in public policy, healthcare delivery, and community support systems. These solutions must be evidence-based, accessible, and tailored to the diverse needs of those affected by OUD.

Moreover, prevention strategies are equally critical in this battle against the opioid epidemic. Public health initiatives that educate about the risks of opioid use, the development of non-addictive pain management alternatives, and early intervention programs are vital. The approval of predictive tests like the AvertD, which identifies individuals at high risk for developing OUD, represents a significant step forward in this regard. By identifying at-risk individuals before they are exposed to opioids, healthcare providers can make more informed decisions about pain management, potentially preventing the onset of addiction. This kind of proactive, preventative approach is a key piece of the complex puzzle in combating the opioid crisis and saving lives.

What is AvertD?

AdvertD Website
The AdvertD website as of January 9th, 2024.

AvertD is a groundbreaking diagnostic tool, marking a significant advancement in the field of personalized medicine and public health. It is a prescription-use only genetic laboratory test designed for individuals aged 18 and older. Utilizing a simple cheek swab DNA sample, AvertD identifies specific genetic variants that are associated with an increased risk of developing Opioid Use Disorder (OUD). This innovative approach to genetic testing allows for a more nuanced understanding of an individual's predisposition to OUD, enabling healthcare providers to tailor their approach to pain management and opioid prescription.

The primary application of AvertD is in the clinical setting before a patient's first exposure to oral opioid medications, typically prescribed for managing acute pain. The test serves as a crucial decision-making tool, providing valuable insights to physicians and patients about the potential risks associated with opioid use. In scenarios where the test indicates a heightened risk of OUD, healthcare providers can explore alternative pain management strategies, thereby mitigating the risk of future addiction. This proactive approach is particularly significant given the complexities of predicting individual responses to opioids, which have historically been a challenge in pain management.

The significance of AvertD lies in its potential to transform how opioids are prescribed and managed. By integrating genetic risk assessment into clinical practice, it opens the door for a more personalized approach to pain treatment, moving away from the one-size-fits-all method that has contributed to the opioid crisis. However, it's crucial to note that AvertD should be used as part of a comprehensive clinical evaluation. It is not intended to be the sole basis for treatment decisions but rather a component of a broader strategy that considers the patient's medical history, pain severity, and other relevant factors. This balanced approach ensures that while genetic risks are accounted for, they are weighed alongside other critical aspects of patient care.

Significance of the Opioid Risk Test AvertD

Significance

The introduction of AvertD into the medical landscape holds profound significance, particularly in the context of the ongoing opioid crisis. As a tool that can identify individuals at an elevated genetic risk for Opioid Use Disorder (OUD), it empowers healthcare professionals to make more informed decisions about prescribing opioids. This is crucial in a landscape where the indiscriminate prescription of opioids has been a key factor in the escalation of addiction rates. By providing a genetic basis for risk assessment, AvertD offers a new level of precision in tailoring pain management approaches to individual patients. This not only helps in reducing the potential for opioid addiction but also underscores the evolving role of personalized medicine in public health.

Moreover, the test symbolizes a significant shift towards preventive healthcare strategies in addressing the opioid epidemic. Instead of solely focusing on treatment and rehabilitation for those already affected by OUD, AvertD provides a proactive approach to prevent the disorder from developing in the first place. This proactive approach aligns with the broader public health goal of reducing the incidence of OUD and its related complications. By integrating such predictive tests into routine medical practice, there's a potential to significantly alter the trajectory of the opioid crisis, paving the way for a future where opioid-related harm is substantially diminished through early intervention and tailored medical care.

The Food & Drug Adminstration (FDA) Approval Process for AvertD

FDA Approval

The journey to Food & Drug Adminstration (FDA) approval for AvertD was marked by a rigorous review process, beginning with a critical evaluation by an advisory committee in October 2022. The committee, comprising experts in genetics, pain management, and addiction medicine, played a pivotal role in scrutinizing the test's efficacy and safety. Based on their recommendations, significant modifications were made to enhance the test's accuracy and reliability. These modifications were aimed at ensuring that AvertD met the stringent standards set by the FDA for medical devices, particularly those that influence critical healthcare decisions like opioid prescription.

A key focus during the development and review process was the identification and mitigation of risks associated with AvertD, primarily the potential for false negatives and positives. False negatives, where the test might fail to identify those at risk, could lead to inappropriate opioid prescriptions, while false positives might result in unnecessary anxiety or denial of effective pain relief. To mitigate these risks, the FDA emphasized the importance of accurate product labeling and comprehensive training for healthcare providers. These measures are intended to ensure that the test's results are interpreted correctly and integrated into a holistic patient assessment, thereby minimizing the likelihood of misinformed clinical decisions.

In its decision-making process, the FDA carefully balanced the inherent uncertainties associated with a novel diagnostic tool like AvertD against the urgent public health need for innovative solutions to the opioid crisis. Recognizing the potential of AvertD to bring a significant change in opioid prescribing practices, the FDA approved the test while also acknowledging the importance of post-market data. This data, gathered from real-world use of the test, will be instrumental in continuously evaluating its performance and impact. The FDA's approach reflects a commitment to advancing public health through the adoption of cutting-edge medical technologies, while also ensuring ongoing monitoring and adaptation based on emerging evidence and clinical experiences.

Other FDA Efforts To Stop The Opioid Crisis Management

Naloxone

In response to the escalating opioid crisis, the FDA has implemented a robust Overdose Prevention Framework, introduced in 2022. This comprehensive strategy is designed to address the multifaceted nature of drug overdose and substance use disorders. The framework emphasizes a holistic approach, focusing on reducing exposure to opioids, preventing new cases of opioid use disorder (OUD), and promoting more effective treatments for those suffering from addiction. It represents the FDA's commitment to leveraging its regulatory authority and scientific expertise to mitigate the devastating impact of the opioid epidemic on American society.

As part of its ongoing efforts, the FDA has also approved several critical measures to combat the overdose crisis. A notable approval is the nonprescription naloxone nasal spray, a life-saving medication designed for emergency treatment of known or suspected opioid overdose. This approval marks a significant milestone in public health efforts, as it allows for wider availability of naloxone, making it more accessible to the general public and potentially saving countless lives. The FDA's actions reflect a proactive stance in not just managing, but actively working to reverse the course of the opioid epidemic through innovative and accessible medical interventions. This approach underscores the agency's dedication to addressing public health challenges with forward-thinking strategies and solutions.

Seeking Help For Addiction To Opioids

Get Help For Addiction. Find A Rehab

In the challenging journey of overcoming addiction to opioids, reaching out for help is a crucial first step. Various national treatment websites and helplines offer resources, support, and guidance to those struggling with opioid use disorder (OUD). Here is a list of some known national treatment resources:

  • Addiction Helpline America:Offering confidential support and resources for individuals facing opioid addiction. Contact them at (844) 561-0606 for assistance.
  • SAMHSA’s National Helpline:The Substance Abuse and Mental Health Services Administration provides a helpline for treatment referral and information. Call 1-800-662-HELP (4357) for 24/7, 365-day-a-year service in English and Spanish.
  • National Institute on Drug Abuse (NIDA):NIDA's website provides extensive information on drug abuse, including research, treatment options, and educational resources. Visit drugabuse.gov for more information.
  • American Addiction Centers:Offering nationwide treatment facilities and an online resource for finding help with addiction. You can reach their helpline at 1-888-439-3435.
  • Partnership to End Addiction:This organization offers personalized support and resources for families dealing with addiction. Access their services at drugfree.org or call their helpline at 1-855-DRUGFREE.
  • Faces & Voices of Recovery:An advocacy organization focused on supporting individuals in recovery and their families. Visit their website at facesandvoicesofrecovery.org for more resources and support.

Questions About Addiction Treatment?

Our Private & Confidential Helpline Is Available 24/7.

Benefits Include:

- Licensed Treatment Centers
- Caring, Supportive Guidance
- Financial Assistance Options

Call Now

Find A Rehab

Browse our directory of addiction treatment centers to find a provider or program that is right for you.

Get Started

Are You An Addiction Treatment Provider?

Help more people by listing your rehab in our directory. Getting listed is fast and simplete. Click the button below to get started.

Submit Your Center

Continue Reading

Photo for Article: Why Seeking Help for Addiction is a Sign of Strength

Why Seeking Help for Addiction is a Sign of Strength

This article challenges the stigma of addiction, showing that seeking help is a courageous step and a true demonstration of strength.

Read Now
Photo for Article: What to Expect When You Call for Help

What to Expect When You Call for Help

Learn what to expect when you call Addiction Helpline America for help with addiction, including the process and benefits of seeking timely assistance.

Read Now
Photo for Article: Unveiling the Connection: Mental Illness and Addiction

Unveiling the Connection: Mental Illness and Addiction

Explore the intricate relationship between mental illness and addiction, understanding the dual approach needed for effective treatment and recovery.

Read Now